254 related articles for article (PubMed ID: 28385075)
21. Definition of biochemical success following primary whole gland prostate cryoablation.
Levy DA; Ross AE; ElShafei A; Krishnan N; Hatem A; Jones JS
J Urol; 2014 Nov; 192(5):1380-4. PubMed ID: 24813344
[TBL] [Abstract][Full Text] [Related]
22. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry.
Shah TT; Peters M; Eldred-Evans D; Miah S; Yap T; Faure-Walker NA; Hosking-Jervis F; Thomas B; Dudderidge T; Hindley RG; McCracken S; Greene D; Nigam R; Valerio M; Minhas S; Winkler M; Arya M; Ahmed HU
Eur Urol; 2019 Jul; 76(1):98-105. PubMed ID: 30638633
[TBL] [Abstract][Full Text] [Related]
23. Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation.
Nyame YA; Elshafei A; Greene DJ; Arora HC; Given RW; Tay KJ; Polascik TJ; Ross AE; Mouraviev VB; Lugnani F; Jones JS
J Endourol; 2017 May; 31(5):497-501. PubMed ID: 28437170
[TBL] [Abstract][Full Text] [Related]
24. Cryoablation for locally advanced clinical stage T3 prostate cancer: a report from the Cryo-On-Line Database (COLD) Registry.
Ward JF; DiBlasio CJ; Williams C; Given R; Jones JS
BJU Int; 2014 May; 113(5):714-8. PubMed ID: 24112776
[TBL] [Abstract][Full Text] [Related]
25. Does neoadjuvant androgen deprivation therapy before primary whole gland cryoablation of the prostate affect the outcome?
Grossgold E; Given R; Ruckle H; Jones JS
Urology; 2014 Feb; 83(2):379-83. PubMed ID: 24315304
[TBL] [Abstract][Full Text] [Related]
26. Association between Lesion Location and Oncologic Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy.
Stabile A; Sanchez-Salas R; Tourinho-Barbosa R; Macek P; Pellegrino F; Gandaglia G; Moschini M; Cathala N; Mombet A; Montorsi F; Briganti A; Cathelineau X
J Urol; 2021 Sep; 206(3):638-645. PubMed ID: 33890485
[TBL] [Abstract][Full Text] [Related]
27. Focal Cryotherapy for Localized Prostate Cancer.
Tay KJ; Polascik TJ
Arch Esp Urol; 2016 Jul; 69(6):317-26. PubMed ID: 27416635
[TBL] [Abstract][Full Text] [Related]
28. Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer.
Williams AK; MartÃnez CH; Lu C; Ng CK; Pautler SE; Chin JL
Eur Urol; 2011 Sep; 60(3):405-10. PubMed ID: 21185115
[TBL] [Abstract][Full Text] [Related]
29. A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate.
Elshafei A; Kovac E; Dhar N; Levy D; Polascik T; Mouraviev V; Yu C; Jones JS
Prostate; 2015 Sep; 75(13):1447-53. PubMed ID: 26172607
[TBL] [Abstract][Full Text] [Related]
30. Associations Between Prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the Prostate.
Elshafei A; Tay KJ; Kara O; Malkoc E; Nyame Y; Arora H; Hatem A; Patel SA; Lugnani F; Polascik TJ; Jones JS
Clin Genitourin Cancer; 2018 Apr; 16(2):e477-e482. PubMed ID: 29174470
[TBL] [Abstract][Full Text] [Related]
31. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
[TBL] [Abstract][Full Text] [Related]
32. Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.
Oishi M; Gill IS; Tafuri A; Shakir A; Cacciamani GE; Iwata T; Iwata A; Ashrafi A; Park D; Cai J; Desai M; Ukimura O; Bahn DK; Abreu AL
J Urol; 2019 Dec; 202(6):1188-1198. PubMed ID: 31347953
[TBL] [Abstract][Full Text] [Related]
33. Primary cryotherapy for localized prostate cancer treatment.
Mercader C; Musquera M; Franco A; Alcaraz A; Ribal MJ
Aging Male; 2020 Dec; 23(5):1460-1466. PubMed ID: 33191831
[TBL] [Abstract][Full Text] [Related]
34. Whole and hemi-gland cryoablation for primary localized prostate cancer: Short and medium-term oncological and functional outcomes.
Bossier R; Sanguedolce F; Territo A; Vanacore D; MartÃnez C; Regis F; Gallioli A; Mercade A; Mosquera L; Aumatell J; Balana J; Carlderon J; Huguet J; Gaya JM; Palou J; Breda A
Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):172-178. PubMed ID: 32033834
[TBL] [Abstract][Full Text] [Related]
35. Oncological outcomes of cryosurgery as primary treatment in T3 prostate cancer: experience of a single centre.
Guo Z; Si T; Yang X; Xu Y
BJU Int; 2015 Jul; 116(1):79-84. PubMed ID: 25168692
[TBL] [Abstract][Full Text] [Related]
36. Early oncological control following partial gland cryo-ablation: a prospective experience specifying reflex MRI guided biopsy of the ablation zone.
Wysock JS; Becher E; Gogaj R; Velazquez N; Lepor H
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):114-119. PubMed ID: 32636487
[TBL] [Abstract][Full Text] [Related]
37. Comparisons of Oncological and Functional Outcomes Between Primary Whole-Gland Cryoablation and High-Intensity Focused Ultrasound for Localized Prostate Cancer.
Liu YY; Chiang PH
Ann Surg Oncol; 2016 Jan; 23(1):328-34. PubMed ID: 26088651
[TBL] [Abstract][Full Text] [Related]
38. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation.
Liu YY; Chiang PH; Chuang YC; Lee WC; Cheng YT; Wang HJ
Ann Surg Oncol; 2015 May; 22(5):1612-7. PubMed ID: 25287436
[TBL] [Abstract][Full Text] [Related]
39. Safety of selective nerve sparing in high risk prostate cancer during robot-assisted radical prostatectomy.
Kumar A; Samavedi S; Bates AS; Mouraviev V; Coelho RF; Rocco B; Patel VR
J Robot Surg; 2017 Jun; 11(2):129-138. PubMed ID: 27435701
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry.
Spiess PE; Levy DA; Pisters LL; Mouraviev V; Jones JS
World J Urol; 2013 Dec; 31(6):1321-5. PubMed ID: 23179729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
